About a year ago, renal denervation procedures won a huge victory after finally being greenlit by FDA. Now two of the frontrunners in the space have received reimbursement.
AtriCure is the latest player to throw its hat into pulsed-field ablation. The Mason, OH-based company revealed plans during an earnings call earlier this week. Michael Carrel, president and CEO, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback